Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 5 vs ELAGOLIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Management of moderate to severe pain associated with endometriosis
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
200 mg orally twice daily
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Not established; safety and efficacy in pediatric patients have not been studied.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
None
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 5 vs ELAGOLIX, answered by our medical review team.
ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 5 and ELAGOLIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 5 and ELAGOLIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.